ResidencyInfectious Diseases Past Residents
Jihye Kim, Pharm.D. (2010-2011):
Dusten T. Rose, Pharm.D. (2009-2010):
I took a full-time Infectious Diseases clinical pharmacist position at Indiana University Hospital in Indianapolis. I am currently involved in the development and implementation of an Antimicrobial Stewardship program for Computerized Physician Order Entry at the academic medical institution. Other aspects of my position include the preceptorship of Butler and Purdue pharmacy students and Clarian Health pharmacy residents, as well as a once-weekly appointment in an Adult ID/HIV outpatient clinic. My current areas of interest and focus include antimicrobial stewardship, microbial resistance mechanisms, opportunistic infections in immunosuppressed patients, and HIV/AIDS.
Mike Sweet, Pharm.D., BCPS (2008-2009):
Following my ID residency, I returned to West Virginia University Hospitals for a unique position performing outcomes research related to infectious diseases. I was selected for a podium presentation at the 49th ICAAC meeting in September 2009 on my residency research project titled “Impact of Vancomycin MIC on Clinical Outcomes in Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infection not Exhibiting Vancomycin Heteroresistance” Additionally, I also presented a poster of another residency project at the IDSA meeting in October 2009 titled “Impact of Infectious Diseases Consultation on Management of Staphylococcus aureus Bacteremia."
Jenana Halilovic Maker, Pharm.D., BCPS (2007-2008):
After completing my ID residency, I took a faculty position at the University of the Pacific School of Pharmacy and continued to work at UC Davis Medical Center as an Infectious Diseases pharmacist. Most recently, I have expanded the clinical pharmacy services to the pediatric ID clinic where I assist in the management of HIV-positive children. I presented a poster of my residency research in 2008 at the 48th Annual ICAAC/IDSA meeting in Washington, D.C. titled “A Retrospective Analysis of Long Term Outcomes of Daptomycin Treatment for Osteomyelitis.”
Brett Heintz, Pharm.D., BCPS (2006-2007):
After completing my infectious diseases pharmacy residency at UC Davis Medical Center in July 2007, I began a full-time position as an assistant professor at Touro University College of Pharmacy (TUCOP). As a faculty member at TUCOP, I coordinate the infectious disease therapeutic coursework in the clinical science track, lecture in pharmaceutical science track, and serve as an active member in curriculum and assessment committees. I continue to maintain a high-level of infectious disease practice at UC Davis Medical Center, focusing on antimicrobial stewardship, including daily patient monitoring, pharmacotherapeutic and pharmacokinetic consultation, management of outpatient parenteral antimicrobial therapy, and precepting. My primary research focuses on appropriate antimicrobial use, including selection, dosing and duration of therapy using microbiologic data, patient specific factors and pharmacokinetic-pharmacodynamic principles. For example, I recently evaluated the optimal antimicrobial dosing among critically ill patients receiving various forms of renal replacement therapy.
